SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-115724
Filing Date
2022-11-08
Accepted
2022-11-08 09:08:17
Documents
14
Period of Report
2022-11-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2229896d1_8k.htm   iXBRL 8-K 25429
2 EXHIBIT 99.1 tm2229896d1_ex99-1.htm EX-99.1 69722
6 GRAPHIC tm2229896d1_ex99-1img001.jpg GRAPHIC 3032
  Complete submission text file 0001104659-22-115724.txt   280528

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nvct-20221108.xsd EX-101.SCH 3033
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvct-20221108_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvct-20221108_pre.xml EX-101.PRE 22595
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2229896d1_8k_htm.xml XML 3574
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

IRS No.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41264 | Film No.: 221367447
SIC: 2834 Pharmaceutical Preparations